Hubbry Logo
ScabiesScabiesMain
Open search
Scabies
Community hub
Scabies
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Scabies
Scabies
Scabies
View on Wikipedia
from Wikipedia

Scabies
Other namesSeven-year itch[1]
Magnified view of a burrowing trail of the scabies mite. The scaly patch on the left was caused by scratching and marks the mite's entry point into the skin. The mite has burrowed to the top-right, where it can be seen as a dark spot at the end.
SpecialtyInfectious disease, dermatology
Symptomsitchiness, pimple-like rash[2]
Usual onset2–6 weeks (first infection), ~1 day (subsequent infections)[2]
CausesSarcoptes scabiei mite spread by close contact[3]
Risk factorsCrowded living conditions (child care facilities, group homes, prisons), lack of access to water, wearing second hand clothing[3][4][5]
Diagnostic methodBased on symptoms[6]
Differential diagnosisseborrheic dermatitis, dermatitis herpetiformis, pediculosis, atopic dermatitis[7]
Medicationpermethrin, crotamiton, lindane, ivermectin[8]
Frequency204 million / 2.8% (2015)[9]

Scabies (/ˈskeɪb(i)iːz/, SKAY-b(ee-)eez;[10] also sometimes known as the seven-year itch)[1] is a contagious human skin infestation by the tiny (0.2–0.45 mm) mite Sarcoptes scabiei,[1][3] variety hominis. The word is from Latin: scabere, lit. 'to scratch'.[11] The most common symptoms are severe itchiness and a pimple-like rash.[2] Occasionally, tiny burrows may appear on the skin from eggs that are about to hatch.[2] In a first-ever infection, the infected person usually develops symptoms within two to six weeks.[2] During a second infection, symptoms may begin within 24 hours.[2] These symptoms can be present across most of the body or just in certain areas such as the wrists, between fingers, or along the waistline.[2] The head may be affected, but this is typically only in young children.[2] The itch is often worse at night.[2] Scratching may cause skin breakdown and an additional bacterial infection in the skin.[2]

Various names have been given to this condition and the name 'seven year itch' has been recorded in many documents from the 1800s.[12] Although the 1952 play The Seven Year Itch and modern treatment methods have generally changed this name to refer to human relationships, the condition was historically very difficult to treat.

Scabies is caused by infection with the female mite Sarcoptes scabiei var. hominis, an ectoparasite.[3] The mites burrow into the skin to live and deposit eggs.[3] The symptoms of scabies are due to an allergic reaction to the mites.[2] Often, only between 10 and 15 mites are involved in an infection.[2] Scabies most often spreads during a relatively long period of direct skin contact with an infected person (at least 10 minutes) such as that which may occur during sexual activity or living together.[3][13] Spread of the disease may occur even if the person has not developed symptoms yet.[14] Crowded living conditions, such as those found in child-care facilities, group homes, and prisons, increase the risk of spread.[3] Areas with a lack of access to water also have higher disease rates.[4] Crusted scabies is a more severe form of the disease, not essentially different but an infestation by huge numbers of mites[3] that typically only affects those with a poor immune system; the number of mites also makes them much more contagious.[3] In these cases, the spread of infection may occur during brief contact or by contaminated objects.[3] The mite is tiny and at the limit of detection with the human eye. It is not readily obvious; factors that aid in detection are good lighting, magnification, and knowing what to look for. Diagnosis is based either on detecting the mite (confirmed scabies), detecting typical lesions in a typical distribution with typical histological features (clinical scabies), or detecting atypical lesions or atypical distribution of lesions with only some histological features present (suspected scabies).[15]

Several medications are available to treat those infected, including oral and topical ivermectin, permethrin, crotamiton, and lindane creams.[8] Sexual contacts within the last month and people who live in the same house should also be treated at the same time.[14] Bedding and clothing used in the last three days should be washed in hot water and dried in a hot dryer.[14] As the mite does not live for more than three days away from human skin, more washing is not needed.[14] Symptoms may continue for two to four weeks following treatment.[14] If after this time symptoms continue, retreatment may be needed.[14]

Scabies is one of the three most common skin disorders in children, along with ringworm and bacterial skin infections.[16] As of 2015, it affects about 204 million people (2.8% of the world population).[9] It is equally common in both sexes.[17] The young and the old are more commonly affected.[6] It also occurs more commonly in the developing world and tropical climates.[6] Other animals do not spread human scabies;[3] similar infection in other animals is known as sarcoptic mange, and is typically caused by slightly different but related mites.[18]

Signs and symptoms

[edit]
Commonly involved sites of rashes of scabies[19]

The characteristic symptoms of a scabies infection include intense itching and superficial burrows.[20] Because the host develops the symptoms as a reaction to the mites' presence over time, typically a delay of four to six weeks occurs between the onset of infestation and the onset of itching. Similarly, symptoms often persist for one to several weeks after successful eradication of the mites. As noted, those re-exposed to scabies after successful treatment may exhibit symptoms of the new infestation in a much shorter period—as little as one to four days.[21]

Itching

[edit]

In the classic scenario, the itch is made worse by warmth and is usually experienced as being worse at night, possibly because distractions are fewer.[20] As a symptom, it is less common in the elderly.[20]

Rash

[edit]

The superficial burrows of scabies usually occur in the area of the finger webs, feet, ventral wrists, elbows, back, buttocks, and external genitals.[20] Except in infants and the immunosuppressed, infection generally does not occur in the skin of the face or scalp. The burrows are created by the excavation of the adult mite in the epidermis.[20] Acropustulosis, or blisters and pustules on the palms and soles of the feet, are characteristic symptoms of scabies in infants.[22]

  • Scabies of the foot
    Scabies of the foot
  • Scabies of the arm
    Scabies of the arm
  • Scabies of the hand
    Scabies of the hand

In most people, the trails of the burrowing mites are linear or S-shaped tracks in the skin, often accompanied by rows of small, pimple-like mosquito or insect bites. Lesions are symmetrical and mainly affect the hands, wrists, axillae, thighs, buttocks, waist, soles of the feet, areola, and vulva in females, and penis and scrotum in males. The neck and above are usually not affected, except in cases of crusted scabies and infestations of infants, the elderly, and the immunocompromised.[22] Symptoms typically appear two to six weeks after infestation for individuals never before exposed to scabies. For those having been previously exposed, the symptoms can appear within several days after infestation. However, symptoms may appear after several months or years.[23]

Crusted scabies

[edit]
Crusted scabies in a person with AIDS

The elderly, disabled, and people with impaired immune systems, such as those with HIV/AIDS, cancer, or those on immunosuppressive medications, are susceptible to crusted scabies (also called Norwegian scabies).[20][23][24] On those with weaker immune systems, the host becomes a more fertile breeding ground for the mites, which spread over the host's body, except the face. The mites in crusted scabies are not more virulent than in noncrusted scabies but are much more numerous, sometimes up to two million. People with crusted scabies exhibit scaly rashes, slight itching, and thick crusts of skin that contain large numbers of scabies mites. For this reason, persons with crusted scabies are more contagious to others than those with typical scabies.[3][25] Such areas make eradication of mites particularly difficult, as the crusts protect the mites from topical miticides/scabicides, necessitating prolonged treatment of these areas.[citation needed]

Cause

[edit]

Scabies mite

[edit]
Main article: Sarcoptes scabiei
Video of the Sarcoptes scabiei mite
Lifecycle of scabies[19]

In the 18th century, Italian biologists Giovanni Cosimo Bonomo and Diacinto Cestoni (1637–1718) described the mite now called Sarcoptes scabiei, variety hominis, as the cause of scabies. Sarcoptes is a genus of skin parasites and part of the larger family of mites collectively known as scab mites. These organisms have eight legs as adults and are placed in the same phylogenetic class (Arachnida) as spiders and ticks.[26]

S. scabiei mites are under 0.5 mm in size; they are sometimes visible as pinpoints of white. Gravid females tunnel into the dead, outermost layer (stratum corneum) of a host's skin and deposit eggs in the shallow burrows. The eggs hatch into larvae in three to ten days. These young mites move about on the skin and molt into a "nymphal" stage, before maturing as adults, which live three to four weeks in the host's skin. Males roam on top of the skin, occasionally burrowing into the skin. In general, the total number of adult mites infesting a healthy hygienic person with non-crusted scabies is small, about 11 females in burrows, on average.[27]

The movement of mites within and on the skin produces an intense itch, which has the characteristics of a delayed cell-mediated inflammatory response to allergens. IgE antibodies are present in the serum and the site of infection, which react to multiple protein allergens in the body of the mite. Some of these cross-react to allergens from house dust mites. Immediate antibody-mediated allergic reactions (wheals) have been elicited in infected persons, but not in those not infected; immediate hypersensitivity of this type is thought to explain the observed far more rapid allergic skin response to reinfection seen in persons who have been infected previously, especially within the previous year or two.[27]

Transmission

[edit]

Scabies is contagious and can be contracted through prolonged physical contact with an infested person.[28] This includes sexual intercourse, although a majority of cases are acquired through other forms of skin-to-skin contact. Less commonly, scabies infestation can happen through the sharing of clothes, towels, and bedding, but this is not a major mode of transmission; individual mites can survive for only two to three days, at most, away from human skin at room temperature.[29][30] As with lice, a latex condom is ineffective against scabies transmission during intercourse, because mites typically migrate from one individual to the next at sites other than the sex organs.[31]

Healthcare workers are at risk of contracting scabies from patients, because they may be in extended contact with them.[32]

Pathophysiology

[edit]

The symptoms are caused by an allergic reaction of the host's body to mite proteins, though exactly which proteins remains a topic of study. The mite proteins are also present in the gut, and in mite feces, which are deposited under the skin. The allergic reaction is both of the delayed (cell-mediated) and immediate (antibody-mediated) type, and involves IgE (antibodies are presumed to mediate the very rapid symptoms on reinfection).[27] The allergy-type symptoms (itching) continue for some days, and even several weeks, after all mites are killed. New lesions may appear for a few days after mites are eradicated. Nodular lesions from scabies may continue to be symptomatic for weeks after the mites have been killed.[27]

Rates of scabies are negatively related to temperature and positively related to humidity.[33]

Diagnosis

[edit]
A photomicrograph of an itch mite (S. scabiei)

Scabies may be diagnosed clinically in geographical areas where it is common when diffuse itching presents along with either a lesion in two typical spots or itchiness is present in another household member.[16] The classical sign of scabies is the burrow made by a mite within the skin.[16] To detect the burrow, the suspected area is rubbed with ink from a fountain pen or a topical tetracycline solution, which glows under a special light. The skin is then wiped with an alcohol pad. If the person is infected with scabies, the characteristic zigzag or S pattern of the burrow will appear across the skin; however, interpreting this test may be difficult, as the burrows are scarce and may be obscured by scratch marks.[16] A definitive diagnosis is made by finding either the scabies mites or their eggs and fecal pellets.[16] Searches for these signs involve either scraping a suspected area, mounting the sample in potassium hydroxide and examining it under a microscope, or using dermoscopy to examine the skin directly.[20]

Differential diagnosis

[edit]

Symptoms of early scabies infestation mirror other skin diseases, including dermatitis, syphilis, erythema multiforme, various urticaria-related syndromes, allergic reactions, ringworm-related diseases, and other ectoparasites such as lice and fleas.[34]

Prevention of passing on scabies to other people

[edit]

Mass-treatment programs that use topical permethrin or oral ivermectin have been effective in reducing the prevalence of scabies in several populations.[16] No vaccine is available for scabies. The simultaneous treatment of all close contacts is recommended, even if they show no symptoms of infection (asymptomatic), to reduce rates of recurrence.[16] Since mites can survive for only two to three days without a host, other objects in the environment pose little risk of transmission except in the case of crusted scabies. Therefore, cleaning is of little importance.[16] Rooms used by those with crusted scabies require thorough cleaning.[35]

Management

[edit]

Treatment

[edit]

Several medications are effective in treating scabies. Treatment should involve the entire household and any others who have had recent, prolonged contact with the infested individual.[16] In addition to treating the infestation, options to control itchiness include antihistamines and prescription anti-inflammatory agents.[36] Bedding, clothing and towels used during the previous three days should be washed in hot water and dried in a hot dryer.[37]

Treatment protocols for crusted scabies are significantly more intense than for common scabies.[8][38][39]

Permethrin

[edit]

Permethrin, a pyrethroid insecticide, is the most effective treatment for scabies,[40] and remains the treatment of choice.[16][41] It is applied from the neck down, usually before sleep, and left on for about 8 to 14 hours, then washed off in the morning.[16] Care should be taken to coat the entire skin surface, not just symptomatic areas; any patch of skin left untreated can provide a "safe haven" for one or more mites to survive. One application is normally sufficient, as permethrin kills eggs, hatchlings, and adult mites, though many physicians recommend a second application three to seven days later as a precaution. Crusted scabies may require multiple applications or supplemental treatment with oral ivermectin (below).[16][41][42] Permethrin may cause slight irritation of the skin that is usually tolerable.[20] In recent years, concern is growing about permethrin-resistant scabies,[43][44] although some researchers refer to this as pseudo-resistance.[45]

Ivermectin

[edit]

Oral ivermectin is effective in eradicating scabies, often in a single dose.[4][16] It is the treatment of choice for crusted scabies, and is sometimes prescribed in combination with a topical agent.[16][20] It has not been tested on infants, and is not recommended for children under six years of age.[20]

Topical ivermectin preparations are effective for scabies in adults.[46] It has also been useful for sarcoptic mange, the veterinary analog of human scabies.[47][48]

One review found that the efficacy of permethrin is similar to that of systemic or topical ivermectin.[49] A separate review found that although oral ivermectin is usually effective for the treatment of scabies, it does have a higher treatment failure rate than topical permethrin.[50] Another review found that oral ivermectin provided a reasonable balance between efficacy and safety.[51] A study has demonstrated that scabies is markedly reduced in populations taking ivermectin regularly;[52] the drug is widely used for treating scabies and other parasitic diseases, particularly among the poor and disadvantaged in the tropics, beginning with the developer Merck providing the drug at no cost to treat onchocerciasis from 1987.[53]

Others

[edit]

Other treatments include lindane, benzyl benzoate, crotamiton, malathion, and sulfur preparations.[16][20] Lindane is effective, but concerns over potential neurotoxicity have limited its availability in many countries.[20] It is banned in California,[54] but may be used in other states as a second-line treatment.[55] Sulfur ointments or benzyl benzoate are often used in the developing world due to their low cost;[20] some 10% sulfur solutions have been shown to be effective,[56] and sulfur ointments are typically used for at least a week, though many people find the odor of sulfur products unpleasant.[20] Crotamiton has been found to be less effective than permethrin in limited studies.[20] Crotamiton or sulfur preparations are sometimes recommended instead of permethrin for children, due to concerns over dermal absorption of permethrin.[16]

  • Day 4
    Day 4
  • Day 8 (treatment begins)
    Day 8 (treatment begins)
  • Day 12 (under treatment)
    Day 12 (under treatment)
  • Healed
    Healed

Communities

[edit]

Scabies is endemic in many developing countries,[16] where it tends to be particularly problematic in rural and remote areas. In such settings, community-wide control strategies are required to reduce the rate of disease, as treatment of only individuals is ineffective due to the high rate of reinfection. Large-scale mass drug administration strategies may be required where coordinated interventions aim to treat whole communities in one concerted effort.[57] Although such strategies have shown to be able to reduce the burden of scabies in these kinds of communities, debate remains about the best strategy to adopt, including the choice of drug.[57][58]

The resources required to implement such large-scale interventions in a cost-effective and sustainable way are significant. Furthermore, since endemic scabies is largely restricted to poor and remote areas, it is a public health issue that has not attracted much attention from policymakers and international donors.[57][58]

Epidemiology

[edit]

Scabies is one of the three most common skin disorders in children, along with tinea and pyoderma.[16] As of 2010, it affects about 100 million people (1.5% of the population) and its frequency is not related to gender.[17] The mites are distributed around the world and equally infect all ages, races, and socioeconomic classes in different climates.[25] Scabies is more often seen in crowded areas with unhygienic living conditions.[59] Globally as of 2009, an estimated 300 million cases of scabies occur each year, although various parties claim the figure is either over- or underestimated.[23][60] About 1–10% of the global population is estimated to be infected with scabies, but in certain populations, the infection rate may be as high as 50–80%.[16]

History

[edit]
Wax figurine of a man with Norwegian scabies

Scabies has been observed in humans since ancient times. Archeological evidence from Egypt and the Middle East suggests scabies was present as early as 494 BC.[21][61] In the fourth century BC, Aristotle reported on "lice" that "escape from little pimples if they are pricked" – a description consistent with scabies.[62] Arab physician Ibn Zuhr is believed to have been the first to provide a clinical description of the scabies mites.[63]

Roman encyclopedist and medical writer Aulus Cornelius Celsus (circa 25 BC – 50 AD) is credited with naming the disease "scabies" and describing its characteristic features.[62] The parasitic etiology of scabies was documented by Italian physician Giovanni Cosimo Bonomo (1663–1696) in his 1687 letter, "Observations concerning the fleshworms of the human body".[62] Bonomo's description established scabies as one of the first human diseases with a well-understood cause.[21][61]

In Europe in the late 19th through mid-20th centuries, a sulfur-bearing ointment called by the medical eponym of Wilkinson's ointment was widely used for topical treatment of scabies. The contents and origins of several versions of the ointment were detailed in correspondence published in the British Medical Journal in 1945.[64]

In the 1995 documentary Anne Frank Remembered, Bloeme Evers-Emden told of how she was selected from Auschwitz and sent to a work camp where conditions were sufficiently improved that she was able to survive until the liberation. She said Anne Frank was rejected for this transfer because she had contracted scabies.[65]

Scabies in animals

[edit]
Main articles: Sarcoptic mange and Acariasis
A street dog in Bali, Indonesia, with sarcoptic mange

Scabies may occur in some domestic and wild animals; the mites that cause these infestations are of different subspecies from the one typically causing the human form.[20] These subspecies can infest animals that are not their usual hosts, but such infections do not last long.[20] Scabies-infected animals experience severe itching and secondary skin infections. They often lose weight and become frail.[27]

The most frequently diagnosed form of scabies in domestic animals is sarcoptic mange, caused by the subspecies Sarcoptes scabiei canis, most commonly in dogs and cats. Sarcoptic mange is transmissible to humans who come into prolonged contact with infested animals,[66] and is distinguished from human scabies by its distribution on skin surfaces covered by clothing. Scabies-infected domestic fowl develop what is known as "scaly leg". Domestic animals that have gone feral and have no veterinary care are frequently affected by scabies.[67] Nondomestic animals have also been observed to develop scabies. Gorillas, for instance, are known to be susceptible to infection by contact with items used by humans,[68] and it is a fatal disease of wombats.[69]

Scabies is also a concern for cattle.[70][71][72][73]

Society and culture

[edit]
Public health worker Stefania Lanzia using a soft toy scabies mite to publicise the condition in a 2016 campaign

The International Alliance for the Control of Scabies was started in 2012,[6][58][74] and brings together over 150 researchers, clinicians, and public-health experts from more than 15 countries. It has managed to bring the global health implications of scabies to the attention of the World Health Organization (WHO).[58] Consequently, the WHO has included scabies on its official list of neglected tropical diseases and other neglected conditions.[75]

Research

[edit]

Moxidectin is being evaluated as a treatment for scabies.[76] It is established in veterinary medicine to treat a range of parasites, including sarcoptic mange. Its advantage over ivermectin is its longer half-life in humans, thus the potential duration of action.[77]

Tea tree oil (TTO) exhibits scabicidal action in a laboratory setting.[78]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Scabies

View on Grokipedia
from Grokipedia
Scabies is a contagious ectoparasitic caused by the microscopic Sarcoptes scabiei var. hominis, which burrows into the upper layer of the skin to lay eggs, triggering an allergic reaction that leads to intense itching and a pimple-like . The female mite tunnels through the , depositing 2–3 eggs per day over her 4–5 week lifespan, while the resulting to mite antigens, feces, and saliva causes the hallmark pruritus, which is often most severe at night. Common manifestations include linear burrows, erythematous papules, and vesicles, typically appearing in skin folds such as between the fingers, on the wrists, elbows, axillae, and genitals, though infants and young children may exhibit widespread involvement including the face, , palms, and soles. In immunocompromised individuals, a severe variant known as crusted (or Norwegian) scabies can develop, characterized by hyperkeratotic crusts containing thousands to millions of mites and posing a heightened transmission risk. Transmission of scabies occurs primarily through prolonged skin-to-skin contact, requiring as little as 10–20 minutes for classic cases, though crusted scabies can spread more readily via brief contact or fomites such as infested , , or towels. Symptoms often do not appear until 2–6 weeks after initial infestation in previously unexposed individuals, allowing carriers to unknowingly propagate outbreaks, particularly in crowded or close-contact settings like households, homes, prisons, and facilities. Globally, scabies affects more than 200 million people at any time and more than 400 million people cumulatively every year, with higher prevalence in tropical regions, resource-poor communities, and among children aged 5–14 years, where rates can reach 5–50% in endemic areas of , , and . The condition is classified as a neglected by the , contributing to significant morbidity through secondary bacterial infections like and post-streptococcal . Diagnosis of scabies relies on clinical presentation, supported by microscopic identification of mites, eggs, or fecal scybala from scrapings, though dermoscopy or tests may aid visualization of burrows in ambiguous cases. Treatment involves scabicidal agents, with first-line options including topical 5% cream applied from the neck down and left on for 8–14 hours, or oral (200 μg/kg, repeated after 1–2 weeks) for classic scabies, while crusted cases may require multiple doses combined with keratolytics and longer regimens. All household and close contacts should be treated simultaneously, even if , to prevent reinfestation, and itching may persist for 2–4 weeks post-treatment due to ongoing . Complications such as bacterial superinfections necessitate antibiotics like topical or oral cephalexin. Prevention strategies emphasize avoiding direct contact with infested individuals and decontaminating potentially fomites by machine-washing in hot (at least 50°C/122°F) followed by high-heat , or sealing non-washable items in bags for at least 72 hours, as mites cannot survive off the human host beyond 2–3 days. Environmental cleaning, including vacuuming of furniture and carpets, further reduces risk in institutional outbreaks, though animal-derived scabies mites (e.g., from dogs or cats) cause temporary, self-limited in humans without reproduction. Mass drug administration with has shown efficacy in controlling community outbreaks in high-prevalence settings.

Clinical Presentation

Typical Signs and Symptoms

Scabies in immunocompetent individuals typically manifests with intense pruritus, which is often more severe at night due to increased activity. This itching arises from a delayed reaction to the , their eggs, and , with symptoms generally beginning 4 to 6 weeks after initial in those not previously exposed, though it can onset within 1 to 4 days in sensitized individuals. The allows for and before the allergic response triggers noticeable discomfort. The characteristic rash consists of erythematous papules, vesicles, and excoriations from scratching, distributed symmetrically in specific body areas. In adults, lesions commonly appear in the interdigital spaces of the hands, wrists, elbows, axillae, waistline, and genital region. In adults, involvement of the head, neck, and scalp is typically spared in classic scabies and is uncommon except in cases of crusted scabies or severe immunocompromise. In children, the rash may also involve the face, , palms, and soles, reflecting differences in skin folding and mite preference. Linear burrows, representing the mites' tunnels, are a hallmark feature, appearing as thin, wavy, grayish-white lines measuring 1 to 10 mm in length on the skin surface. Scratching due to pruritus frequently leads to secondary bacterial infections, such as or , particularly from and . These complications arise from breaches in the skin barrier, increasing the risk of localized or systemic spread if untreated. In typical cases, symptoms progress from initial burrowing to widespread and itching without the hyperkeratotic plaques seen in crusted variants.

Crusted Scabies

Crusted scabies, also known as Norwegian scabies, represents a severe, hyperinfestive form of scabies caused by an extraordinarily high burden of mites, often numbering in the thousands to millions within the skin. This leads to widespread, thick, crusted, and hyperkeratotic lesions that can cover extensive areas of the body, including the , face, , trunk, extremities, and , where subungual and may occur. Unlike typical scabies, which features limited mite numbers and intense pruritus, crusted scabies often presents with minimal or absent initial itching due to the host's impaired , allowing unchecked proliferation. As the condition progresses, symptoms may evolve to include severe complications such as bacterial superinfections from pathogens like or , potentially leading to , , or even mortality if untreated. This variant predominantly affects immunocompromised individuals, including those with , organ transplant recipients on immunosuppressive therapy, elderly patients with or frailty, and individuals with conditions limiting mobility or self-care, such as or severe . The hyperkeratotic crusts result from excessive keratin production in response to the massive load, creating a scaly, fissured surface that flakes off easily. Crusted scabies is highly contagious, far exceeding the transmission risk of typical scabies, due to the shedding of vast numbers of mites and eggs in skin debris, scales, and crusts, which can contaminate environments and fomites like bedding, clothing, or furniture. This makes indirect transmission from surfaces more feasible than in typical cases but remains uncommon for brief public contacts, such as sitting on bus seats, given the mites' limited off-host survival of 24-72 hours. This poses significant outbreak risks in institutional settings, such as nursing homes, long-term care facilities, and hospitals, where close contact and shared items facilitate rapid spread among residents and staff. Diagnosis of crusted scabies is challenging because its atypical presentation—lacking the classic burrows, papules, and intense itch of standard scabies—often leads to initial misdiagnosis as conditions like , eczema, seborrheic dermatitis, or . The extensive scaling and erythroderma can mimic these dermatoses, delaying recognition until microscopic examination of skin scrapings reveals the profuse mites, eggs, and fecal matter confirmatory of the infestation.

Etiology and Pathogenesis

Causative Agent

Scabies is caused by the mite var. hominis, an obligate ectoparasite belonging to the class , subclass Acari, and family . This microscopic measures 0.2–0.4 mm in length, with adults possessing four pairs of short, stubby legs equipped with claws and empodia for burrowing. Females are larger, typically 0.30–0.45 mm long and 0.25–0.35 mm wide, while males are smaller at 0.20–0.24 mm long and 0.15–0.20 mm wide; the mite's body is oval, dorsally convex, and ventrally flat, covered in fine spines. The lifecycle of S. scabiei var. hominis occurs entirely on the host's and consists of four stages: , , , and adult, completing in 10–17 days under optimal conditions. Upon mating, the gravid female burrows tortuous tunnels into the of the , where she deposits 2–3 s per day for up to 4–5 weeks, producing a total of 40–50 eggs during her 1–2 month lifespan. Eggs are oval, measuring 0.10–0.15 mm, and hatch in 3–4 days into hexapod larvae with three pairs of legs, which then migrate to the skin surface to form molting pouches. Larvae develop through two nymphal stages—protonymph and tritonymph, each with four pairs of legs—over 3–4 days before emerging as adults to continue the cycle. The variant S. scabiei var. hominis is specifically adapted to s, thriving at surface temperatures of 32–35°C and neutral levels characteristic of . This adaptation enables efficient burrowing and reproduction in the warm, moist environment of , with optimal activity between 30–37°C. Off the host, S. scabiei var. hominis survives only briefly, up to 2–3 days in cool (10–21°C), conditions with relative above 75–97%, but viability drops sharply in dry or hot environments, with death occurring within 24–48 hours at (21°C) and 40–80% . The mite elicits an allergic response through antigens in its fecal pellets, known as scybala, and ; these contain proteins such as serpins and S-transferases that trigger type I (immediate) and type IV (delayed) reactions in the host.

Transmission Mechanisms

Scabies is primarily transmitted through prolonged direct -to-skin contact with an infested individual, typically requiring at least 10 to 20 minutes of close interaction, such as occurs between sexual partners, household members, or caregivers. This mode is most efficient in intimate or crowded settings, including households, prisons, and homes, where sustained physical proximity facilitates mite transfer from burrows in the host's . Indirect transmission via fomites, such as infested , , or towels, is possible but less common in typical cases due to the 's limited off the host, which ranges from 24 to 72 hours under optimal and humidity conditions. In contrast, crusted scabies—a severe form with millions of mites—is highly contagious through fomites, as the heavy mite burden allows rapid spread even with brief contact or shared items. Individuals become contagious shortly after , often asymptomatically during the early phase before symptoms appear ( of 2 to 6 weeks for first-time infestations), and remain so from the start of egg-laying until approximately 24 to 48 hours after effective treatment eradicates the mites and eggs. Transmission risk is amplified by factors such as , poor personal , and institutional living environments like or homeless shelters, which promote frequent close contacts. Scabies is not spread by casual contact, such as handshakes or hugs, nor by acting as vectors; animal-to-human transmission occurs only rarely in zoonotic cases involving mites adapted to hosts. Global outbreaks are often linked to social determinants like , which exacerbate and limited access to resources.

Pathophysiological Processes

The female mite initiates infestation by burrowing into the of the human epidermis, excavating tunnels approximately 1-10 mm in length using its mouthparts and forelegs while secreting containing proteolytic enzymes to dissolve the surrounding and tissue. This process, which takes about 20 minutes for adult females, allows the mite to feed on liquefied epidermal cells, intercellular fluids, and lymph, while laying 2-3 eggs per day and depositing fecal pellets (scybala) within the burrow. Over the course of 2-4 weeks, the eggs hatch into larvae that continue the colonization, with mite densities typically reaching 10-15 adults in ordinary scabies, though burrows remain confined to the uppermost skin layers without penetrating deeper . Initial often remains for 2-6 weeks as the host develops immune to antigens, including salivary proteins, fecal extracts, and excretory-secretory products released during burrowing. Upon re-exposure or during persistent , this triggers an IgE-mediated reaction, where -specific IgE binds to mast cells and , leading to and release. Concurrently, a type IV delayed response develops, dominated by Th1, Th2, and Th17 + T-cell activation against antigens, resulting in production (e.g., IL-4, IL-5, IL-13, IL-17, IL-31) that recruits and promotes epidermal ; IL-31, produced by Th2 cells and macrophages, is a primary mediator of the intense, nocturnal pruritus. Transcriptomic studies have identified upregulation of such as CXCL8 and in lesional skin, contributing to the inflammatory milieu. The inflammatory cascade culminates in the formation of papules, vesicles, and burrows as and macrophages infiltrate the , responding to accumulated scybala and debris that provoke a localized granulomatous reaction. This type IV response, peaking 4-6 weeks post-infestation, upregulates pro-inflammatory cytokines such as TNF-α and IL-8, exacerbating barrier disruption and , while -derived immunomodulators (e.g., complement inhibitors in feces) further dampen innate defenses, including suppression of , to favor parasite survival and secondary bacterial infections. Vigorous scratching due to pruritus causes excoriations that breach the compromised skin barrier, facilitating secondary bacterial invasion, particularly by and , leading to , , or abscesses. In severe cases, S. pyogenes can trigger post-streptococcal through immune complex deposition or via molecular mimicry. Mite secretions that inhibit host complement activation enhance bacterial adherence and proliferation within lesions, amplifying infection risk. In crusted (Norwegian) scabies, host factors such as impaired T-cell immunity—often in immunocompromised individuals (e.g., those with , organ transplants, or elderly frailty)—permit unchecked proliferation, with burdens exceeding millions and minimal inflammatory response due to reduced Th1 production and IL-10 dysregulation. This leads to hyperkeratotic crusts laden with mites and eggs, as defective fails to mount the typical and granulomatous reactions seen in ordinary scabies.

Diagnosis

Clinical Assessment

The clinical assessment of scabies begins with a detailed history taking to identify key features suggestive of . Patients typically report intense pruritus that worsens nocturnally, often starting 2 to 6 weeks after initial exposure, though sensitized individuals may experience symptoms within 1 to 4 days of reinfestation. Inquiring about close skin-to-skin contact with infested individuals, such as household members or sexual partners, is essential, as scabies spreads primarily through prolonged direct contact. A history of similar symptoms in close contacts or household outbreaks further supports suspicion, particularly in settings like facilities. Physical examination focuses on identifying characteristic lesions and their distribution, performed under adequate lighting with a full-body . Primary lesions include erythematous s, vesicles, or excoriations, commonly distributed in webs, flexor surfaces of wrists, elbows, axillae, umbilicus, waistline, , and genitalia, with genital involvement more frequent in males. s, the hallmark sign, appear as linear or tracks, 1 to 10 mm long, often whitish or skin-colored, ending in a minute vesicle or containing the ; they are most visible in non-keratinized areas like finger webs and wrists. To enhance detection, the burrow ink test involves applying to a suspicious site, gently rubbing it in, and wiping off excess with an alcohol swab, revealing the as a persistent dark, wavy line. Magnification aids in burrow confirmation during examination. Under dermoscopy at 10x , burrows may show as a linear tract with scybala (fecal pellets) resembling a "jet with " or "jetliner trail," while the itself appears as a "delta sign"—a triangular, brown-black structure at the burrow's end. These visualizations of , eggs, or feces improve diagnostic accuracy, with dermoscopy demonstrating high when performed by trained clinicians. In at-risk populations, such as the immunocompromised (e.g., those with , , or elderly individuals), red flags for crusted scabies include widespread hyperkeratotic, scaling lesions on the , hands, feet, or trunk, often with reduced pruritus despite a high burden of thousands to millions. If clinical findings are atypical, brief consideration of differential diagnoses or confirmatory tests may be warranted to exclude mimics.

Differential Diagnosis

Scabies can be challenging to diagnose clinically due to its similarity to other pruritic skin conditions, necessitating consideration of the patient's history, lesion distribution, and specific features to rule out mimics. Accurate differentiation is crucial, as misdiagnosis may lead to inappropriate treatments and delayed management of the infestation. Among pruritic dermatoses, often presents with flexural involvement, a personal or family history of , and generalized dry, eczematous patches without the pathognomonic burrows seen in scabies. , in contrast, is typically localized to areas of or irritant exposure, with a clear history of such contact and no burrows or evidence. Other infestations that mimic scabies include , characterized by visible lice nits or adults on hair shafts but lacking burrows, and bites, which produce punctate, transient pruritic papules often in clusters without linear tracks. The crusted (Norwegian) variant of scabies must be distinguished from hyperkeratotic conditions like severe , though the former features thick crusts with numerous mites rather than well-demarcated plaques. Additional differentials encompass eczema, which shares itchy, inflamed skin but lacks nocturnal intensification of pruritus and burrows; , marked by silvery-scaled plaques on extensor surfaces with less intense itching; urticaria, presenting with evanescent wheals that resolve within hours; and drug eruptions, often accompanied by systemic symptoms like fever or . Key differentiators for scabies include the presence of linear burrows, particularly in spaces, wrists, and genitals, along with a history of close contact with infested individuals, which are absent in most mimics. In cases of ambiguity, or microscopic examination can confirm the by identifying mites, eggs, or scybala. In children and the elderly, overlapping conditions such as diaper rash or seborrheic dermatitis may occur, but scabies is guided by its characteristic distribution (e.g., avoiding the face in adults) and epidemiological context like institutional outbreaks.

Confirmatory Tests

When clinical diagnosis of scabies is uncertain, confirmatory tests provide objective evidence by detecting the mite , its eggs, or fecal remnants. These methods are employed selectively, as clinical suspicion often suffices, but they are essential in atypical presentations or low-burden infestations. Skin scraping is the traditional and most accessible method for confirmation. The procedure entails applying to a or unexcoriated , then using a sterile or needle to gently scrape the skin surface and collect scales from the . The material is transferred to a glass slide with a drop of , covered with a coverslip, and examined under light at 10x-40x for screening and 200x-400x for confirmation; for crusted scabies, 10% KOH may be added to dissolve excess prior to examination. Adult female mites (0.30-0.45 mm long by 0.25-0.35 mm wide), ovoid eggs (0.10-0.15 mm), larvae, or scybala (fecal pellets) are identifiable. This test offers high specificity (near 100%) but moderate sensitivity (approximately 56%), with yield improved in crusted scabies due to higher mite density in hyperkeratotic lesions. Adhesive tape test provides a simpler, less invasive option suitable for children or fragile . Clear cellophane tape is pressed firmly onto a suspected , such as a or , and quickly peeled off to capture superficial debris, which is then adhered sticky-side down to a glass slide for microscopic examination. Staining with ink or may enhance visibility of structures. This method detects mites, eggs, or scybala with a sensitivity of about 68% and specificity of 100%. Dermoscopy and videodermatoscopy enable rapid, non-invasive visualization using a handheld device with 10x-20x magnification, often aided by immersion fluid like alcohol. Characteristic findings include the "delta sign" or "jet with ," where the appears as a brown triangular structure at the burrow's end, eggs as blue ovals along linear tracks (S-shaped or wavy burrows 1-10 mm long), and scybala as delta-wing patterns. Videodermatoscopy offers enhanced resolution for deeper burrows or extraction. These techniques achieve a sensitivity of 90-91% and are valuable when is unavailable, though specificity is lower (around 86%). Molecular tests, primarily real-time PCR, target S. scabiei DNA from skin scrapings, swabs, or biopsies using specific primers for genes like cytochrome c oxidase subunit 1 (cox1). After DNA extraction, amplification detects mite presence even in low-burden or post-treatment cases where mites are scarce. Sensitivity reaches 81-100% depending on the assay, with specificity of 92%, making it useful for research or outbreaks but limited by cost, need for specialized equipment, and non-routine status in clinical practice. Skin biopsy is infrequently performed due to its invasiveness but serves as a definitive option in ambiguous cases. A 3-4 mm punch or shave biopsy from an active lesion is fixed in formalin, embedded in paraffin, sectioned at 3-5 µm thickness, and stained with hematoxylin and eosin (H&E). Histopathology reveals intracorneal mites, eggs, or scybala within the stratum corneum, often with secondary epidermal changes like acanthosis (thickening) and spongiosis (intercellular edema). Polarized light may highlight mite spines. This approach confirms diagnosis but is reserved for when other tests fail.

Prevention

Individual Preventive Measures

Individuals can prevent scabies infestation by minimizing direct skin-to-skin contact with infested persons, as the mite is primarily transmitted through prolonged physical contact. Avoiding sharing personal items such as clothing, towels, or bedding that have been in contact with an infested individual further reduces transmission risk. Maintaining good personal hygiene practices, including frequent handwashing with soap and water, daily bathing, and regular changing of clothes, supports overall prevention efforts, though these measures alone do not eliminate the . In high-risk settings such as healthcare facilities or crowded living environments, wearing gloves or long-sleeved clothing acts as a barrier to minimize skin exposure during close interactions. Post-exposure prophylaxis is recommended for close contacts of confirmed cases, including household members, even if , to prevent secondary infestations; this typically involves a single application of 5% cream or two oral doses of (200 µg/kg each, administered 7–14 days apart), administered simultaneously with treatment of the . is essential to eliminate mites from personal surroundings: machine-wash clothes, , and used in the three days prior to treatment in hot water exceeding 50°C (122°F) for at least 10 minutes, followed by drying on a hot cycle, or opt for . For non-washable items, seal them in a closed for 3 to 7 days, as scabies mites cannot survive more than 2 to 3 days without contact. Vacuuming carpets, furniture, and mattresses, followed by disposing of the vacuum bag, helps remove any potential mites or eggs. Education on early symptom recognition empowers individuals to act promptly: intense itching, especially at night, along with linear burrows or papules on areas like the wrists, fingers, or genital region, should prompt isolation from close contacts and immediate consultation to initiate treatment and prevent spread.

Community and Institutional Strategies

In endemic areas with scabies prevalence exceeding 10%, mass drug administration (MDA) programs involve screening high-risk populations, such as those in remote communities or institutional settings, followed by prophylactic treatment with oral at a dose of 200 μg/kg, typically administered in two doses 7–14 days apart to ensure efficacy. Ongoing large-scale MDA programs are implemented in countries including , , , and . Such interventions have demonstrated substantial reductions in prevalence, with one community trial in the reporting an 88% decrease from 18.7% to 2.3% within 12 months, highlighting the value of targeting entire populations to interrupt transmission. In institutional outbreaks, like those in schools or prisons, similar screening of new entrants and exposed individuals is recommended, coupled with treatment to prevent resurgence. Isolation protocols in institutions emphasize contact precautions to limit spread, including the use of gloves and gowns during care for suspected or confirmed cases, while avoiding direct skin-to-skin contact. Infested individuals should be quarantined in a single room until at least 24 hours after the first treatment dose, after which they may return to general areas if precautions continue; for crusted scabies, isolation persists until treatment completion. Cohort nursing, where infested residents are grouped together under enhanced monitoring, is applied in facilities like nursing homes to contain outbreaks without full facility . Surveillance efforts in communities and institutions focus on active monitoring of infestation rates, with routine screening of at-risk groups and mandatory reporting of outbreaks to authorities to enable rapid response. The (WHO) endorses such systems as part of neglected tropical diseases (NTD) control, recommending simplified prevalence mapping tools for early detection in high-burden settings like refugee camps or hospitals. Institutional protocols include maintaining records of cases and notifying other facilities of transfers involving infested individuals to prevent cross-institution transmission. Education campaigns play a crucial role in community prevention by raising awareness of scabies transmission through prolonged skin contact, thereby reducing stigma and promoting early reporting and treatment adherence. These initiatives, often delivered via community health workers, emphasize practices like hot-water washing of bedding and encourage household-wide treatment to break transmission chains, with proven benefits in increasing MDA participation in low-resource areas. In institutions, staff training on recognition and precautions fosters a vigilant environment, minimizing undetected spread. Integration of scabies control into broader NTD programs allows for coordinated MDA with interventions against other parasitic diseases, such as , optimizing resources in low-income settings as outlined in the WHO NTD Roadmap 2021–2030. This approach targets universal health coverage by 2030, with milestones including MDA implementation in 25 endemic countries by 2030 and enhanced to track progress toward reducing scabies as a problem. Ongoing supports co-administration of with antibiotics like to address secondary bacterial infections, further streamlining integrated efforts.

Treatment

Topical Therapies

Topical therapies serve as the cornerstone of scabies treatment, utilizing scabicidal creams or lotions applied directly to the skin to eliminate mites and their eggs. These agents are preferred for their targeted action and safety profile in standard cases, with emerging as the first-line option due to its high efficacy and broad applicability, though emerging resistance may reduce effectiveness in some settings. Permethrin 5% cream is the recommended first-line topical treatment for scabies, effective against both mites and eggs with cure rates exceeding 90% after a single application and up to 98% with the standard regimen in low-resistance areas. In Bangladesh, local studies have shown topical 5% permethrin to be more effective than oral ivermectin, with significantly faster resolution of lesions and itching. However, recent studies as of 2025 indicate increasing resistance, with failure rates of 10-20% or higher in endemic regions, potentially lowering cure rates. It is applied to clean, dry from the neck down, covering all areas including , genitals, and the soles of the feet, and left on for 8-14 hours before washing off. A repeat application is typically performed after 1-2 weeks to address any newly hatched mites. This treatment is safe for individuals aged 2 months and older, including pregnant and people, though consultation with a healthcare provider is advised for infants. Proper application guidelines are essential for success, requiring thorough coverage of the entire body surface to ensure contact with all mites, which may be concentrated in interdigital spaces, wrists, and elbows. If the patient bathes or showers before the recommended 8-hour minimum contact time, the application must be repeated. All household members and close contacts should be treated simultaneously, regardless of symptoms, to prevent reinfestation. When is unavailable, contraindicated, or ineffective due to resistance, alternative topical agents include 25% lotion, which is applied to the entire body for 24 hours, repeated on day 2 and day 7, though it can cause and is generally avoided in children under 2 years and during . 10% cream or lotion offers a milder option that may soothe post-treatment itching but is less effective than , with frequent treatment failures reported, and is not recommended for children. For infants under 2 months or pregnant individuals, ointment at 5-10% concentration is a safe alternative, applied nightly for three consecutive nights and repeated weekly as needed, despite its unpleasant odor and messy application limiting patient adherence. Spinosad 0.9% suspension, FDA-approved in 2021 for patients aged 4 years and older, is another alternative for classic scabies, applied topically and left on for 10 minutes before rinsing, with limited long-term data but good tolerability. Adherence challenges, such as incomplete application or failure to treat contacts, often lead to treatment persistence and reinfestation. Additionally, post-treatment itching, known as post-scabies syndrome, can persist for 2-4 weeks due to to dead mites and , requiring symptomatic with antihistamines or topical corticosteroids rather than additional scabicide. In cases of treatment failure, systemic options like oral may be considered for non-responders.

Systemic Treatments

Systemic treatments for scabies primarily involve oral , an antiparasitic agent effective against the , recommended as a first-line alternative to topical therapies by health authorities such as the CDC and WHO. works by paralyzing and killing the mites, achieving cure rates of approximately 90-95% with appropriate dosing, though it penetrates the skin less effectively than some topicals. It is particularly indicated for patients with widespread infestations, those who are non-adherent to topical applications, or in institutional outbreaks where ease of administration is crucial. Oral ivermectin is also recommended for crusted scabies, outbreak management, and mass drug administration (MDA) programs; for example, in WHO-supported campaigns in Rohingya refugee camps in Bangladesh, ivermectin is preferred over topical permethrin for logistical reasons, with permethrin used only for contraindications. As with other scabicides, guidelines strongly recommend treating all household members and close contacts simultaneously with ivermectin, even if asymptomatic, to prevent reinfestation and ongoing transmission. Treating at different times is not recommended, as it increases the risk of reinfestation from untreated individuals, though the medication itself does not pose additional safety risks when dosed properly. The standard regimen consists of a single oral dose of 200 mcg/kg body weight, repeated after 1-2 weeks to target newly hatched mites, with doses taken on an empty stomach for optimal absorption. For example, a 60 kg adult would receive 12 mg, typically as four 3 mg tablets. is recommended only for individuals weighing more than 15 kg due to limited safety data in younger children, and it is contraindicated in (FDA pregnancy category C), , or regions endemic for , where it risks serious from rapid parasite death. Monitoring post-treatment involves assessing for symptom resolution within 2-4 weeks, with follow-up skin scrapings if needed to confirm eradication. Advantages of include its systemic action, which simplifies treatment for extensive or crusted scabies, and its utility in mass drug administration campaigns for community control, as endorsed by the WHO. Common side effects are mild, such as gastrointestinal upset or transient itching due to a Mazzotti-like reaction from dying mites, while rare severe effects like may occur in high-risk populations. In crusted or treatment-resistant cases, combination therapy with oral and a topical scabicide like 5% is recommended to enhance efficacy and reduce recurrence, according to recent clinical guidelines. Emerging reports also note potential resistance to in some areas.

Management in Special Cases

Crusted scabies, also known as Norwegian scabies, requires intensified management due to the hyperinfestation with thousands of s and extensive scaling, often in immunocompromised individuals. Treatment typically involves a combination of oral at 200 μg/kg on days 1 and 2, followed by days 8 and 9, or up to three to seven weekly doses in severe cases, alongside repeated applications of topical 5% every 1-2 weeks. Keratolytic agents such as 5-10% in petrolatum or 40% cream are essential to soften and remove thick crusts, facilitating mite penetration by scabicides, and should be applied daily under occlusion until crusts resolve. Patients often require hospitalization for isolation to prevent transmission, along with meticulous wound care to address secondary bacterial superinfections like or , which may necessitate systemic antibiotics like topical or oral cephalexin. In pregnant or breastfeeding women, 5% cream remains the preferred first-line treatment, classified as FDA B with demonstrated safety in multiple studies showing no increased risk of adverse fetal outcomes. Oral should be avoided due to limited safety data in and potential transfer to . As an alternative, 6-10% ointment applied daily for three days, repeated after one week, is considered safe and effective for this population, though it may cause more skin irritation. For infants and young children, 5% cream is approved from two months of age and applied to the entire body, including the , face (avoiding eyes and ), and , with a repeat application after 7-14 days to account for higher burdens and burrows in these areas. 25% lotion serves as a second-line option but must be diluted to 12.5% for children under 5 years or infants to minimize irritation, applied twice daily for three days and repeated after one week, also covering the in young patients where infestations are more common. Spinosad may be considered for children ≥4 years if permethrin fails. Permethrin resistance has been documented in scabies cases, particularly in regions like with high treatment prevalence, where 2024 reports indicate failure rates exceeding 20% in some communities due to genetic mutations in mite voltage-gated sodium channels; as of 2025, resistance is escalating globally with average failure rates around 10% but higher in endemic areas. In such resistant infections, clinicians should switch to oral (200 μg/kg, two doses one week apart) as the primary alternative, with emerging trials of moxidectin (a longer-acting ) showing promise in single-dose regimens for refractory cases, though not yet standard or approved for scabies as of 2025. Follow-up evaluation is crucial 2-4 weeks after treatment initiation to assess for persistent burrows or live mites via skin scraping or dermoscopy, with retreatment recommended if persists. Post-scabetic , affecting up to 50% of patients for 2-6 weeks due to to dead mites and , can be managed symptomatically with oral antihistamines like hydroxyzine or diphenhydramine for nocturnal relief, and topical corticosteroids such as 1% to reduce , alongside emollients to soothe xerosis.

Outbreak Control

Effective outbreak control for scabies requires rapid case identification through symptom-based screening and in affected households, institutions, or communities. Health authorities recommend conducting surveys for pruritic rashes and burrows, particularly in high-risk settings like nursing homes or refugee camps, to detect cases early and map transmission networks. This approach facilitates targeted interventions and prevents widespread dissemination, as outbreaks can persist for months without prompt action. Mass drug administration (MDA) serves as a cornerstone for containing endemic outbreaks, involving treatment of entire populations in areas with scabies prevalence exceeding 10%. The endorses MDA using two doses of oral (200 µg/kg body weight, administered 7–14 days apart) for all residents and close contacts, achieving prevalence reductions of up to 79% in systematic reviews. Such approaches have been implemented in settings like the Rohingya refugee camps in Bangladesh, where ivermectin has been the preferred agent in WHO-led campaigns. Alternatively, topical 5% can be used where ivermectin is contraindicated, with coverage targets of at least 80% to interrupt transmission. Such programs have been implemented successfully in Pacific Island nations, demonstrating substantial declines in both scabies and secondary bacterial infections. Environmental measures complement pharmacological interventions by reducing mite survival outside the host. Communal areas should be vacuumed and disinfected, while shared , , and are machine-washed in hot water (at least 50°C) and dried on high heat, or sealed in plastic bags for 72 hours to 7 days if laundering is unavailable. These steps are repeated if reinfestation occurs, as s survive up to 48–72 hours off the body, potentially facilitating resurgence in crowded settings. Monitoring and evaluation are essential to assess outbreak resolution, involving post-treatment follow-up to track cure rates (typically aiming for >90% clinical resolution) and reinfection incidence through repeat screenings at 2–4 weeks. Public health reporting ensures coordination, with outbreaks declared over after two incubation periods (up to 8 weeks) without new cases. In low-resource settings, outbreak control faces significant hurdles, including drug disruptions and poor treatment compliance due to logistical barriers and limited health infrastructure. Integrating scabies MDA with broader and neglected programs enhances feasibility and , addressing overlapping challenges like and deficits.

Epidemiology

Global Burden and Prevalence

The Global Burden of Disease Study 2021 estimated that scabies had a global of 206.6 million cases and an incidence of 622.5 million new cases. In tropical and resource-poor regions, prevalence among children can reach 5–50%, while hyperendemic areas in the Pacific Islands report rates exceeding 30% in some communities. Recognized by the (WHO) as a neglected (NTD) since 2017, scabies contributes significantly to morbidity through secondary bacterial infections, with occurring in up to 70% of cases, particularly among children in endemic areas, and potentially leading to severe complications such as acute . The disease imposes a substantial burden, particularly in low- and middle-income countries, where it accounts for a large proportion of dermatological consultations. Prevalence remains stable at less than 1% in developed countries but has shown increases in crowded settings such as camps and post-COVID institutional environments, with surges noted in high-income nations like those in , including a tripling of incidence in in 2024 compared to pre-pandemic averages. Geographically, the highest rates occur in resource-limited areas of and , where environmental and socioeconomic factors drive endemic transmission. Seasonal peaks often align with dry and cool months, when increased indoor crowding facilitates spread. The intense pruritus of scabies disrupts sleep and daily activities, leading to reduced productivity and absenteeism from work or school. Crowding, a key transmission driver, exacerbates prevalence in vulnerable populations.

Risk Factors and At-Risk Populations

Scabies susceptibility is influenced by various demographic factors that facilitate close physical contact and transmission. Children under 15 years of age are at heightened risk due to their increased interpersonal interactions, such as playing and sharing bedding in schools or households, leading to higher prevalence rates in this group. Elderly individuals, particularly those in long-term care facilities, face elevated risk from reduced mobility, shared living spaces, and potential declines in personal hygiene practices. In certain institutional settings like prisons or dormitories, males may experience higher incidence owing to communal sleeping arrangements and close-contact activities, though overall sex-based differences vary by context. Environmental conditions significantly contribute to scabies transmission by promoting survival and human proximity. Overcrowded housing, such as in urban slums or family dwellings with multiple occupants, increases skin-to-skin contact opportunities, amplifying outbreak potential. Poor and exacerbate this vulnerability by limiting access to clean and bedding, fostering conditions for fomite transmission. Tropical climates further favor scabies persistence, as warmer temperatures and humidity extend the 's viability outside the host, contributing to endemicity in regions like the Western Pacific and . Health-related factors impair host defenses or enable secondary spread among contacts. Immunosuppression from conditions like , long-term corticosteroid use, or heightens susceptibility, often resulting in severe crusted scabies with heavy mite burdens. Malnutrition weakens skin integrity and , particularly in resource-poor areas, increasing infestation risk. Close household or familial contacts of infested individuals represent a primary at-risk group due to prolonged direct contact, necessitating concurrent evaluation to curb transmission. Occupational exposures elevate risk for those in frequent-contact roles. Healthcare workers encounter scabies through patient interactions and fomites in clinical settings, with outbreaks reported in hospitals where unrecognized cases facilitate spread. Daycare staff and educators face similar hazards from children's close play, contributing to institutional transmission in childcare environments. Social determinants, including and migration, underpin many scabies risks by entrenching environmental and health vulnerabilities. Impoverished communities often contend with inadequate and resources, perpetuating cycles of infestation. Migrants and refugees in camps experience particularly high —ranging from 20% to over 50% in some outbreaks—due to and disrupted access to care, as highlighted in recent reviews of displaced populations.

History

Early Descriptions and Recognition

Descriptions of skin conditions resembling scabies, referred to as an "itch," appear in ancient Egyptian medical texts such as the , dating to approximately 1500 BCE, where it was treated with applications of mixed with animal fats. In the 4th century BCE, the Greek philosopher provided one of the earliest detailed accounts, describing scabies as "lice in the flesh" that caused contagious itchy eruptions and noting the presence of burrows from which the parasites could be extracted if pricked. The condition was first named "scabies," from the Latin scabere meaning "to scratch," by Roman encyclopedist in the CE; he characterized it as a highly pruritic, contagious eruption and recommended topical compounds as an effective remedy. Biblical references to "zaraath" in ancient texts from the around the 5th century BCE likely encompassed scabies among other skin diseases, with -rich bathing in the prescribed as a treatment. In medieval , scabies was managed through herbal and mineral remedies, such as applications of , mercury, , , and aromatic plants like ginger or basil, as described by figures like in the 12th century, though it was frequently linked to poor hygiene or supernatural causes. A pivotal advancement occurred in 1687 when Italian physicians Giovan Cosimo Bonomo and Giacinto Cestoni used early to observe and extract live scabies mites from burrows, demonstrating their role in causing the itch and egg-laying within the skin; their observations, emphasizing the disease's contagiousness, were detailed in a letter published in 1703. By the , scabies was formally classified as a type of , an infestation by mites of the genus Acarus (later identified as ), with Ferdinand von Hebra's work in the confirming the mite's causative role and the disease's direct transmissibility through contact, independent of humoral influences. Prior to these discoveries, pre-modern views often attributed scabies to imbalances in bodily humors like excess or , or even to moral sins, fostering stigma and reliance on ineffective oral purges rather than topical interventions.

Advances in Understanding and Treatment

In the early , the lifecycle of was further confirmed through detailed observational studies, building on earlier microscopic identifications and establishing the mite's burrowing and egg-laying behaviors as key to its transmission. Sulfur ointments, used since antiquity, remained a cornerstone of treatment, while emerged as a standard topical scabicide by due to its acaricidal properties and relative efficacy against the . These agents provided symptomatic relief but were limited by poor patient compliance and skin irritation. During the mid-20th century, particularly in the , dichlorodiphenyltrichloroethane () was trialed as a scabicide amid wartime efforts to control ectoparasites, showing initial promise in eradicating mites but ultimately abandoned due to its and environmental persistence. Post-World War II, scabies gained recognition as a significant issue, with outbreaks in crowded settings prompting organized delousing programs and highlighting the need for scalable interventions in resource-limited areas. The 1970s and 1980s marked a pivotal shift with the development of , a synthetic introduced in 1979 as the first highly effective topical scabicide, offering superior kill rates and reduced toxicity compared to prior options. Concurrently, , derived from isolated in 1975 from the bacterium , was identified as a broad-spectrum agent, later adapted for scabies with oral dosing that targeted both mites and their lifecycle stages. In the late , the term "Norwegian" or crusted scabies dates to , when it was described among leprosy patients in . Its strong association with immunocompromised states, including , was further emphasized in clinical studies from the onward, distinguishing it from classical scabies by hyperinfestation with millions of mites. Community-based control programs were implemented in endemic regions during this period. The later integrated scabies into its framework in 2017, spurring global control efforts. Entering the , scabies was officially classified as a neglected by the WHO in 2017, underscoring its global burden and spurring coordinated elimination efforts. Reports of resistance to and emerged in the 2000s, documented in clinical cases and studies showing reduced susceptibility in mite populations from treated areas. As of 2025, phase 2b trials of moxidectin, an oral macrocyclic related to , are evaluating its potential as a single-dose treatment for scabies, including in resistant cases, with preclinical data suggesting advantages in and efficacy.

Scabies in Animals

Animal Hosts and Variants

Sarcoptes scabiei is a highly adaptable with a broad host range, infesting over 100 species of mammals worldwide, including domestic, wild, and companion animals such as dogs, pigs, , foxes, and coyotes. Different variants of the mite are host-specific, with notable examples including S. scabiei var. canis in dogs, var. suis in pigs, and var. equi in . The morphology and lifecycle of S. scabiei in animals are generally similar to those in humans, featuring a burrowing habit where adult females excavate tunnels in the of the skin to deposit eggs. The complete lifecycle spans approximately 17-21 days and includes egg, larval, nymphal (protonymph and tritonymph), and adult stages, all occurring on the host. While the mites exhibit no unequivocal morphological differences across hosts, genetic adaptations contribute to host specificity, such as subtle variations in structure or leg morphology that enhance survival in particular . In infested animals, clinical manifestations typically include intense pruritus leading to self-trauma, alopecia, hyperkeratosis, and crusting of the skin, often starting in sparsely haired areas like the ears, elbows, and . These signs characterize sarcoptic mange, a highly contagious condition within the same species, as seen in dogs where severe infestations can generalize across the body, causing secondary bacterial infections and debilitation. Similar presentations occur in pigs and , with pigs showing papular eruptions and rubbing against objects due to itching. Sarcoptic mange imposes significant veterinary and economic burdens, particularly in production, where it leads to reduced , decreased , and poorer feed conversion efficiency, resulting in substantial financial losses for farmers. In pigs, chronic infestations can cause condemnation at slaughter and increased treatment costs. Veterinary management often involves topical or systemic acaricides, such as applied topically or lime-sulfur dips administered weekly for 4-6 treatments to eliminate mites and prevent spread. Genetic analyses reveal distinct strains of S. scabiei adapted to specific hosts, with variations in mitochondrial and nuclear DNA markers indicating limited between animal and human populations. The human strain (var. hominis) rarely establishes sustained infestations in animals due to strong host preferences driven by these genetic differences, which influence survival and reproduction outside their primary host.

Zoonotic Transmission to Humans

Zoonotic transmission of scabies from animals to humans is infrequent and typically involves variants adapted to animal hosts, such as var. canis from dogs, which cause transient, self-limiting infestations in rather than sustained human scabies. These animal-derived mites induce pruritic papulovesicular rashes resembling human scabies but without burrows, resolving spontaneously within 1-4 weeks as the mites die off. Individuals at risk include pet owners with close contact to infested dogs, veterinarians, farmers handling like or sheep, and workers in environments such as kennels or zoos where outbreaks can occur among animals. Transmission happens through direct skin-to-skin contact with affected animals or indirectly via contaminated bedding or environments, with dogs being the most common source globally. Pathophysiologically, animal mites burrow into human skin and elicit an causing intense itching and , but they cannot reproduce or complete their lifecycle on human hosts due to host specificity, resulting in limited and temporary infestations. This contrasts with human-adapted mites, as animal variants lack the adaptations needed for long-term survival on people, though rare cases of persistence beyond a month have been documented. Diagnosis relies on a detailed clinical history of recent contact combined with characteristic symptoms like rapid-onset pruritus on the trunk, , or limbs; confirmatory of scrapings may reveal the variant mites, though they are often not found due to the transient nature. Dermoscopy can aid in visualization, but empirical assessment is common when exposure history is clear. Prevention centers on treating the infested animal source with appropriate acaricides, such as or dips, to eliminate the reservoir and halt transmission. In humans, symptomatic relief with topical antipruritics like calamine lotion or oral antihistamines suffices, as scabicides are unnecessary given the self-resolving course; avoiding contact with potentially infested animals is advised for at-risk groups.

Society and Culture

Public Health Impact and Stigma

Scabies is frequently stigmatized as a "dirty " due to misconceptions linking it to poor personal hygiene and , despite evidence that transmission primarily occurs through close skin contact in overcrowded conditions rather than individual uncleanliness. This perception originates from cultural associations with socioeconomic disadvantage, leading to feelings of among affected individuals and significant delays in seeking treatment, as people fear judgment or social repercussions. In resource-limited settings, such views perpetuate a cycle where scabies is seen as a marker of moral or personal failing, further entrenching psychological barriers to care. The stigma surrounding scabies profoundly impacts affected individuals, causing , disrupted personal relationships, and from or work due to intense itching and of spreading the . Patients often experience and withdrawal, with community members avoiding contact, which exacerbates issues such as anxiety, depression, and reduced ; for instance, studies indicate moderate to severe impairment in daily activities and self-perception among adults. In communities with high , like remote or impoverished areas, this of contagion disrupts social cohesion and amplifies the psychological toll. Cultural variations in stigma are evident across societies; in parts of , scabies is sometimes attributed to supernatural causes like or curses, equating infection with moral failings and leading to rejection or shaming within families and communities. Among Indigenous groups, such as Aboriginal and Torres Strait Islander populations in , high endemic rates are tied to broader inequities, including and limited access to treatment. Recent 2024 highlights an elevated burden, including low and potential depression, underscoring the need for targeted support. High prevalence in vulnerable populations further fuels these stigmatizing attitudes. Public health efforts, particularly through the (WHO), address stigma by integrating scabies into the 2021–2030 roadmap, which promotes community education to dispel myths about hygiene and contagion, thereby improving case reporting and treatment uptake. These initiatives emphasize inclusive control strategies, such as mass drug administration, to normalize scabies as a treatable condition rather than a source of shame. Gender dynamics compound the issue, as women, who often serve as primary caregivers for children, bear disproportionate blame and emotional overburden during outbreaks, facing heightened stigma and isolation that affects their mental .

Economic and Social Consequences

Scabies imposes substantial direct medical costs, particularly in low-income settings where treatment accessibility is limited. In Fiji, the average cost for a primary healthcare presentation related to scabies is approximately US$17.7 per case, while presentations for associated skin and soft tissue infections (SSTIs) average US$18.3. Hospitalizations for scabies-related complications, such as SSTIs, incur higher expenses, with an average cost of US$439 per admission in the same context. In many low- and middle-income countries (LMICs), these direct costs—encompassing medications, clinic visits, and topical treatments like permethrin—can represent a significant portion of monthly household income, often equivalent to one week's earnings for affected families. further amplify the economic burden through lost and educational disruptions. Scabies-related itching and discomfort lead to missed workdays for caregivers and affected adults, as well as school absences for children, restricting family income and in impoverished communities. In resource-limited areas, these absences exacerbate financial strain, with families in bearing the brunt due to the need for multiple treatment rounds and household decontamination. On a broader scale, scabies outbreaks strain healthcare systems and widen social inequalities, particularly in overcrowded urban slums and endemic regions. The condition contributes to an estimated annual healthcare expenditure of US$3.0 million in alone, or US$3.3 , highlighting resource diversion from other priorities. Globally, scabies accounted for 5.3 million disability-adjusted life years (DALYs) lost in , with the burden disproportionately higher in areas co-endemic with other , underscoring its role in perpetuating cycles of . Policy interventions, such as mass drug administration (MDA) with , demonstrate cost-effectiveness by reducing case numbers and total treatment expenses compared to routine care, potentially yielding long-term savings through decreased transmission and complications.

Research Directions

Emerging Challenges and Resistance

One of the primary emerging challenges in scabies management is the development of resistance to , the first-line topical treatment, particularly in regions with high treatment prevalence. Reports indicate increasing treatment failures attributed to -resistant Sarcoptes scabiei mites in , especially among Indigenous communities, and in parts of such as and , where clinical non-response rates have reached up to two-thirds in some cohorts. This resistance is largely driven by knockdown resistance (kdr) mutations, such as the M918L polymorphism in the voltage-sensitive (VSSC) gene, which reduces the neurotoxic effects of by altering its binding affinity to the mite's nerve cells. These genetic changes have been detected in mite populations exposed to repeated applications, underscoring the selective pressure from widespread use. Ivermectin, an oral alternative, faces limitations in severe cases like crusted scabies due to its suboptimal penetration into hyperkeratotic lesions, necessitating multiple doses and adjunctive keratolytic measures to achieve efficacy. Although true resistance remains rare, evidence of reduced susceptibility has emerged through alterations in glutamate-gated channels, the primary target of ivermectin, which prolongs influx and ; mutations here can diminish this effect, as documented in isolated treatment-refractory cases. Diagnostic challenges further complicate scabies control, as traditional skin scrapings exhibit low sensitivity—often below 50%—in early infestations or low-burden cases, where mites are scarce and burrows subtle. Molecular methods, such as point-of-care PCR targeting mite DNA (e.g., subunit 1 ), offer superior sensitivity approaching 95% on swabs or scrapings, enabling rapid detection but are hindered by high costs and limited accessibility in resource-poor settings. Climate change exacerbates transmission risks by potentially altering environmental conditions that favor survival off-host; warmer and more humid climates could extend viability from days to weeks in favorable microhabitats, facilitating prolonged contamination and interpersonal spread in overcrowded areas. Secondary bacterial co-infections, particularly caused by and , represent another growing obstacle, with rising antibiotic resistance complicating management; methicillin-resistant S. aureus (MRSA) strains are increasingly isolated from scabies-associated lesions, leading to severe complications like post-streptococcal in endemic regions.

Future Therapeutic and Preventive Approaches

Ongoing research into new scabicides aims to address limitations of current treatments by developing agents with improved efficacy and pharmacokinetic profiles. Moxidectin, a macrocyclic lactone with a longer half-life than ivermectin, is under investigation as a single-dose oral therapy for scabies. Phase 2b clinical trials, such as NCT05875441, are evaluating single doses of 8 mg, 16 mg, or 32 mg moxidectin against standard ivermectin (200 mcg/kg) for potential higher cure rates at day 28 in adults, with recruitment completed in 2024. A dose-finding study (NCT03905265), completed and updated in 2025, is assessing safety and acaricidal activity, positioning moxidectin as a promising alternative for mass drug administration (MDA) in endemic areas. Experimental topical agents, including essential oils like tea tree oil, show in vitro acaricidal effects against Sarcoptes scabiei mites, killing them within 30-90 minutes at 5-10% concentrations, and are being explored as adjuvants to conventional therapies. Vaccine development represents a long-term for scabies prevention, focusing on recombinant to induce protective immunity across strains. Preclinical studies have identified paramyosin as a candidate , with recombinant forms (rPmy) eliciting immune responses in animal models that reduce burdens and fertility. Other recombinant proteins, such as those derived from Ssag1 and Ssag2 , have been tested in rabbits, producing IgG antibodies but requiring further optimization for cross-strain protection. These efforts aim to target conserved proteins for broad-spectrum immunity, potentially integrating with neglected (NTD) control programs. Advancements in diagnostics are enhancing early detection in resource-limited settings. AI-assisted dermoscopy applications, like ScabAI, use on mobile devices to analyze images for scabies lesions, achieving high sensitivity in screening clinical and dermoscopic photos. Multiplex PCR assays, including portable Biomeme qPCR platforms, enable simultaneous detection of scabies DNA alongside other NTD pathogens in field samples, improving diagnostic accuracy from scrapings. Preventive approaches emphasize integrated and innovative strategies to curb transmission. Conceptual applications of , such as CRISPR-based editing to induce sterility in mites, build on the mite's sequenced and existing RNAi tools for , offering a future method. Integrating scabies control into onchocerciasis MDA programs has shown feasibility, with combined ivermectin dosing reducing scabies prevalence by up to 79% in co-endemic regions. Research priorities for 2025 highlight the need for enhanced resistance surveillance and MDA optimization to achieve elimination in high-burden hotspots, including monitoring rising incidence trends in regions like the (from 99 to 1341 episodes per 100,000 patient-years between 2014 and 2023). Recent reviews underscore monitoring and resistance through genomic surveillance, alongside refining MDA protocols for sustained coverage and co-reduction.

References

  1. https://www.who.int/news-room/fact-sheets/detail/scabies
  2. https://www.cdc.gov/scabies/about/index.html
  3. https://www.mayoclinic.org/diseases-conditions/scabies/symptoms-causes/syc-20377378
  4. https://www.ncbi.nlm.nih.gov/books/NBK544306/
  5. https://www.cdc.gov/scabies/signs-symptoms/index.html
  6. https://www.cdc.gov/dpdx/scabies/index.html
  7. https://dermnetnz.org/topics/scabies
  8. https://publications.aap.org/redbook/book/755/chapter/14081359/Scabies
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC8743988/
  10. https://www.racgp.org.au/afp/2017/may/scabies-a-clinical-update
  11. https://www.cdc.gov/scabies/hcp/clinical-overview/index.html
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC9223105/
  13. https://www.cdc.gov/scabies/php/public-health-strategy-crusted/index.html
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC6060176/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC5477759/
  16. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/sarcoptes-scabiei
  17. https://doi.org/10.1016/S0190-9622(84)70151-4
  18. https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/sarcoptes-scabiei
  19. https://pubmed.ncbi.nlm.nih.gov/16282315/
  20. https://www.cdc.gov/scabies/causes/index.html
  21. https://emedicine.medscape.com/article/1109204-overview
  22. https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-017-2234-1
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC10909795/
  24. https://pubmed.ncbi.nlm.nih.gov/31087686/
  25. https://www.researchgate.net/publication/394277893_Scabies_An_updated_review_from_epidemiology_to_current_controversies_and_future_perspectives
  26. https://www.frontiersin.org/journals/tropical-diseases/articles/10.3389/fitd.2024.1429266/full
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3222761/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC11589009/
  29. https://www.uptodate.com/contents/scabies-epidemiology-clinical-features-and-diagnosis
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC4911127/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC8776561/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC9976840/
  33. https://jamanetwork.com/journals/jamadermatology/fullarticle/423201
  34. https://www.sciencedirect.com/science/article/abs/pii/S0190962206022547
  35. https://www.cmaj.ca/content/178/12/1540
  36. https://www.cdc.gov/scabies/prevention/index.html
  37. https://www.nhsborders.scot.nhs.uk/media/197859/scabies-June-2014.pdf
  38. https://www.cdc.gov/scabies/php/public-health-strategy/index.html
  39. https://www.cdc.gov/std/treatment-guidelines/ectoparasitic.htm
  40. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30790-4/fulltext
  41. https://www.health.vic.gov.au/infectious-diseases/scabies-control-guidelines
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC8366162/
  43. https://www.cdc.gov/scabies/hcp/clinical-care/index.html
  44. https://www.mdpi.com/2077-0383/13/18/5511
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC1117314/
  46. https://www.banglajol.info/index.php/JSSMC/article/view/48956/35399
  47. https://academic.oup.com/bjd/article/190/2/163/7251446
  48. https://academic.oup.com/bjd/article/190/4/486/7478651
  49. https://www.mayoclinic.org/diseases-conditions/scabies/diagnosis-treatment/drc-20377383
  50. https://emedicine.medscape.com/article/1109204-treatment
  51. https://www.cdc.gov/scabies/treatment/index.html
  52. https://pubmed.ncbi.nlm.nih.gov/24791346/
  53. https://www.aafp.org/pubs/afp/issues/2003/0915/p1089.html
  54. https://www.who.int/bangladesh/news/detail/29-01-2024-who-implements-large-scale-ivermectin-based-mda-for-one-million-rohingya-refugees
  55. https://www.bop.gov/resources/pdfs/scabies3.pdf
  56. https://medlineplus.gov/druginfo/meds/a607069.html
  57. https://www.drugs.com/pregnancy/ivermectin.html
  58. https://www.mayoclinic.org/drugs-supplements/ivermectin-oral-route/description/drg-20064397
  59. https://ijdvl.com/wonder-drug-for-worms-a-review-of-three-decades-of-ivermectin-use-in-dermatology/
  60. https://onlinelibrary.wiley.com/doi/10.1111/ijd.17327
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC11432065/
  62. https://clinicaltrials.gov/study/NCT05875441
  63. https://odh.ohio.gov/wps/portal/gov/odh/know-our-programs/infectious-disease-control-manual/section6/section-6-scabies
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC9522411/
  65. https://health.maryland.gov/phpa/pages/scabies-guidelines.aspx
  66. https://www.nj.gov/health/cd/documents/faq/scabies_guidance.pdf
  67. https://tropmedhealth.biomedcentral.com/articles/10.1186/s41182-021-00348-6
  68. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009661
  69. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012775
  70. https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-12039-2
  71. https://www.medscape.com/viewarticle/scabies-rise-worldwide-even-high-income-countries-2025a1000ccw
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC11613430/
  73. https://www.sciencedirect.com/science/article/pii/S1477893925000845
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC1865595/
  75. https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-021-02721-0
  76. https://jag.journalagent.com/z4/download_fulltext.asp?pdir=hnhjournal&plng=eng&un=HNHJ-29200
  77. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09167-6
  78. https://www.sciencedirect.com/science/article/pii/S1470211824007449
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC11589026/
  80. https://actasdermo.org/en-causes-cures-skin-diseases-in-articulo-S1578219017301622
  81. https://historyofdermatology.org/giovan-cosimo-bonomo/
  82. https://jsstd.org/von-hebra-legend-in-dermatology/
  83. https://stacks.cdc.gov/view/cdc/7614/cdc_7614_DS1.pdf
  84. https://www.epa.gov/ingredients-used-pesticide-products/ddt-brief-history-and-status
  85. https://achh.army.mil/history/book-wwii-internalmedicinevoliii-chapter20/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC9128908/
  87. https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-4362.1976.tb00173.x
  88. https://www.mdpi.com/2414-6366/3/3/98
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC5708620/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC4644327/
  91. https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-topics/sarcoptic-mange-scabies
  92. https://www.merckvetmanual.com/integumentary-system/mange/mange-in-pigs
  93. https://www.merckvetmanual.com/integumentary-system/mange/mange-in-dogs-and-cats
  94. https://www.nature.com/articles/s41598-019-47892-0
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC4675569/
  96. https://www.petmd.com/dog/conditions/skin/c_dg_sarcoptic_mange
  97. https://vcahospitals.com/know-your-pet/mange-sarcoptic-in-dogs
  98. https://pubmed.ncbi.nlm.nih.gov/10548286/
  99. https://www.sciencedirect.com/science/article/pii/S1198743X15007880
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC8877739/
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC6974396/
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC9987785/
  103. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012429
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC10188156/
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC8483324/
  106. https://www.mja.com.au/journal/2024/221/10/scabies-clinical-update
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC7926948/
  108. https://www.scirp.org/journal/paperinformation?paperid=138572
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC11466383/
  110. https://academic.oup.com/bjd/article/184/2/237/6599717
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC8007207/
  112. https://www.frontiersin.org/journals/health-services/articles/10.3389/frhs.2024.1279762/full
  113. https://pubmed.ncbi.nlm.nih.gov/37356045/
  114. https://academic.oup.com/cid/article/39/1/e8/318131
  115. https://academic.oup.com/bjd/article/183/5/808/6600227
  116. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009149
  117. https://journals.asm.org/doi/10.1128/jcm.00073-15
  118. https://www.theguardian.com/global-development/2023/oct/30/malawi-battles-outbreak-of-scabies-that-health-experts-link-to-climate-crisis
  119. https://www.mdpi.com/2414-6366/10/5/135
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC4063749/
  121. https://pmc.ncbi.nlm.nih.gov/articles/PMC10810391/
  122. https://bjgpopen.org/content/early/2025/08/06/BJGPO.2025.0037
Add your contribution
Related Hubs
User Avatar
No comments yet.